Tyra Biosciences (TYRA) Preferred Stock Liabilities (2020 - 2021)

Tyra Biosciences (TYRA) posted Preferred Stock Liabilities of $106.1 million for Q2 2021, up 107.5% on a QoQ basis from $51.1 million in Q1 2021.

Tyra Biosciences (TYRA) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends

Tyra Biosciences' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $106.1 million for Q2 2021.

Quarterly Preferred Stock Liabilities changed N/A year-over-year to $106.1 million in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $106.1 million (changed N/A YoY) and the FY2020 annual result came in at $27.7 million, changed N/A from the prior year.
Preferred Stock Liabilities was $106.1 million for Q2 2021 at Tyra Biosciences, up from $51.1 million in the prior quarter.
Across five years, Preferred Stock Liabilities topped out at $106.1 million in Q2 2021 and bottomed at $27.7 million in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Tyra Biosciences	1.90 Bn	1.90 Bn	-	-

Download Data